Fulgent Genetics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $322.7M | $283.5M | $289.2M | $619.0M | $992.6M |
| Cost of revenue | $191.8M | $176.3M | $184.8M | $252.1M | $215.5M |
| Gross profit | $130.9M | $107.2M | $104.5M | $366.9M | $777.1M |
| Research and development | $53.9M | $48.8M | $41.4M | $28.9M | $24.2M |
| Operating expenses | $222.0M | $181.1M | $300.0M | $188.4M | $101.1M |
| Operating income | -$91.1M | -$73.9M | -$195.5M | $178.5M | $676.0M |
| Interest expense | $75,000 | $170,000 | $488,000 | $346,000 | $117,000 |
| Pretax income | -$70.0M | -$52.0M | -$174.1M | $184.0M | $677.3M |
| Income tax expense | -$8.4M | -$8.1M | $1.2M | $42.1M | $174.8M |
| Net income | -$60.5M | -$42.7M | -$167.8M | $143.4M | $507.4M |
| Balance Sheet | |||||
| Cash and equivalents | $50.2M | $55.1M | $97.5M | $79.5M | $164.9M |
| Current assets | $550.5M | $353.6M | $507.8M | $627.9M | $612.0M |
| Total assets | $1.2B | $1.2B | $1.2B | $1.4B | $1.3B |
| Current liabilities | $85.0M | $72.9M | $73.0M | $88.1M | $105.3M |
| Total liabilities | $106.8M | $90.8M | $102.0M | $116.2M | $112.8M |
| Stockholders' equity | $1.1B | $1.1B | $1.1B | $1.3B | $1.2B |
| Cash Flow Statement | |||||
| Cash from operations | -$101.6M | $21.1M | $27.0M | $253.5M | $538.6M |
| Depreciation and amortization | $24.1M | $24.9M | $26.1M | $32.7M | $11.0M |
| Stock-based compensation | $39.6M | $44.5M | $42.9M | $32.6M | $15.9M |
| Capital expenditure | $22.6M | $40.3M | $22.2M | $18.8M | $23.8M |
| Free cash flow | -$124.2M | -$19.3M | $4.8M | $234.7M | $514.8M |
| Share repurchases | $10.9M | $225,000 | $25.1M | $74.3M | — |
| Impairments | $9.9M | $10.1M | $120.2M | — | $0 |
Shares outstanding 28.4M · Free float 24.3%
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.